Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data
Open Access
- 17 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Infectious Diseases and Therapy
- Vol. 9 (3), 625-639
- https://doi.org/10.1007/s40121-020-00322-5
Abstract
Introduction An extensive clinical development program showed that the meningococcal serogroup B-factor H binding protein (MenB-FHbp) vaccine affords protection against MenB disease for adolescents and adults. Data were pooled from multiple studies within the program to examine whether MenB-FHbp immunogenicity was influenced by sex, age, or race. Methods Immunogenicity was assessed in subjects from seven studies who received 120 µg MenB-FHbp (at 0, 2, 6 months) and had evaluated immune responses against four representative test strains via serum bactericidal assays using human complement (hSBAs). Immune responses were presented by sex (male, female), age group (10–14, 15–18, 19–25, 10–25 years), and race (white, black, Asian, other). Results Among 8026 subjects aged 10–25 years included in this analysis, MenB-FHbp elicited robust immune responses in a high percentage of subjects regardless of demographic characteristics. Across all test strains and demographic subsets, a ≥ 4-fold rise in titer from baseline was achieved in 76.7–95.0% of subjects, with no major differences by sex, age groups assessed, or races evaluated. Corresponding percentages achieving titers ≥ the lower limit of quantification (LLOQ) against all four strains combined were 79.7–87.3% (sex), 81.6–85.5% (age), and 80.0–88.1% (race). Minor differences were observed for geometric mean titers and percentages of subjects achieving titers ≥ LLOQ against each strain based on demographics. Conclusion These data suggested no clinically meaningful differences in MenB-FHbp immunogenicity when administered as a three-dose schedule based on sex, ages assessed, or races evaluated. This analysis supports the continued recommended use of MenB-FHbp to prevent MenB disease in adolescents and young adults. Trial Registration ClinicalTrials.gov identifiers, NCT00808028, NCT01830855, NCT01323270, NCT01461993, NCT01461980, NCT01352845, and NCT01299480.Keywords
Funding Information
- Pfizer Inc
This publication has 39 references indexed in Scilit:
- Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young WomenThe Journal of Infectious Diseases, 2012
- HPV vaccine: an overview of immune response, clinical protection, and new approaches for the futureJournal of Translational Medicine, 2010
- Comparative Efficacy of Inactivated and Live Attenuated Influenza VaccinesNew England Journal of Medicine, 2009
- Immunogenicity of Routinely Used Childhood Vaccines When Coadministered With the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV)The Pediatric Infectious Disease Journal, 2009
- The 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Coadministered With DTPw-HBV/Hib and Poliovirus Vaccines: Assessment of ImmunogenicityThe Pediatric Infectious Disease Journal, 2009
- Safety and efficacy of neonatal vaccinationEuropean Journal of Immunology, 2009
- Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005)Archives of Internal Medicine, 2008
- Meningococcal surrogates of protection?serum bactericidal antibody activityVaccine, 2005
- Differential Immune Responses to Primary Measles-Mumps-Rubella Vaccination in Israeli ChildrenClinical and Vaccine Immunology, 2004
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969